CEBPE

CEBPE encodes a bZIP transcription factor of the C/EBP family that is essential for terminal granulocytic differentiation and secondary granule gene expression. CEBPE expression is controlled by an autoregulatory +6-kb enhancer bound by both CEBPA and CEBPε, and its transcriptional activity at secondary granule gene promoters requires recruitment through SMARCD2-containing SWI/SNF chromatin-remodeling complexes (PMID:28369034, PMID:30952671). CEBPε function depends on nuclear localization, DNA-binding capacity, and interactions with co-factors GATA-1 and PU.1; loss-of-function mutations that disrupt any of these properties cause specific granule deficiency (SGD), while a gain-of-function Arg219His mutation increases genome-wide chromatin occupancy and drives constitutive inflammasome activation (PMID:40581342, PMID:31201888). Beyond myeloid differentiation, CEBPε directly represses adaptive unfolded protein response genes (ERN1, XBP1, ATF6), suppressing plasma cell survival in multiple myeloma (PMID:40347515).

1. 1995 Medium

   Identifying CEBPE as a novel C/EBP-family bZIP transcription factor and mapping it to mouse chromosome 14 (syntenic with human 14q11.2) established the gene's molecular identity and family membership.

   Evidence Chromosomal mapping, cDNA sequencing, and Northern analysis

   PMID:8530045

   Open questions at the time

   • No functional role or target genes defined
   • Expression pattern across hematopoietic lineages not resolved
2. 2017 High

   Demonstrating that CEBPε requires SMARCD2-containing SWI/SNF complexes for recruitment to secondary granule gene promoters — and that SGD-causing mutations abolish this interaction — established the chromatin-remodeling mechanism underlying terminal granulocyte differentiation.

   Evidence ChIP, reciprocal Co-IP, Smarcd2 knockout mice, and patient CEBPE mutation analysis

   PMID:28369034

   Open questions at the time

   • Structural basis of CEBPε–SMARCD2 interaction unknown
   • Whether other SWI/SNF subunits are independently required not tested
3. 2018 Medium

   Identification of CARD10 as a direct CEBPε target gene during granulopoiesis, and the discovery that a Val218Ala mutation prevents nuclear localization causing SGD, revealed both a downstream effector and a critical requirement for nuclear entry.

   Evidence ChIP on Card10 locus in Cebpe-KO mice plus knockdown in human lines; subcellular localization and proteomic analysis of patient neutrophils with V218A mutation

   PMID:29651288 PMID:29773596

   Open questions at the time

   • Full repertoire of direct CEBPε target genes in granulopoiesis not defined
   • Mechanism by which V218A disrupts nuclear import not characterized
4. 2019 High

   Discovery that a +6-kb enhancer mediates autoregulatory feedback by CEBPA and CEBPε on CEBPE expression, and that the gain-of-function R219H mutation dysregulates hundreds of genes including NLRP3/caspase-5 inflammasome components, defined both the upstream regulatory circuit and the consequences of unchecked CEBPε activity.

   Evidence 4C-seq, CRISPRi, germline enhancer deletion in mice, ChIP (enhancer study); ChIP-seq, RNA-seq, inflammasome assays in patient macrophages (R219H study)

   PMID:30952671 PMID:31201888

   Open questions at the time

   • Other transcription factors contributing to +6-kb enhancer activity not identified
   • How R219H structurally reduces repressor association not resolved
5. 2022 Medium

   Characterization of a homozygous frameshift variant (c.655_665del) as transcriptionally inactive and associated with aberrant TLR signaling linked SGD to innate immune pathway dysregulation beyond granule deficiency.

   Evidence Luciferase reporter assay, TLR signaling by flow cytometry, and RT-PCR in patient-derived cells

   PMID:35726044

   Open questions at the time

   • Whether TLR signaling defects are a direct transcriptional consequence of CEBPε loss or secondary
   • Only one patient studied
6. 2025 Medium

   Biochemical dissection of CEBPε variants showed the del11 frameshift loses DNA binding, nuclear localization, and GATA-1/PU.1 interactions (SGD-1a), whereas the ΔRS missense variant retains DNA binding but loses co-factor interactions (SGD-1b), establishing that CEBPε function requires both DNA-binding capacity and co-factor partnerships.

   Evidence Forced expression in ES cells and NIH3T3 cells with DNA-binding, subcellular localization, and protein–protein interaction assays

   PMID:40581342

   Open questions at the time

   • Genome-wide transcriptional consequences of SGD-1b versus SGD-1a not compared
   • Whether ΔRS variant retains SMARCD2 interaction not tested
7. 2025 Medium

   Identification of CEBPε as a direct transcriptional repressor of adaptive UPR genes (ERN1, XBP1, ATF6) downstream of ZMYND8/H3K36me2 extended its function beyond myeloid differentiation into plasma cell biology.

   Evidence Co-IP, ChIP-seq, RNA-seq, and ZMYND8 knockdown in multiple myeloma cells

   PMID:40347515

   Open questions at the time

   • Whether CEBPε directly binds UPR gene promoters or acts indirectly not fully resolved
   • Relevance to normal plasma cell differentiation not tested

• The structural basis of CEBPε interaction with SMARCD2/SWI/SNF and GATA-1/PU.1, the complete set of direct transcriptional targets during granulopoiesis, and how gain-of-function mutations alter repressor association remain unresolved.
• No crystal or cryo-EM structure of CEBPε in complex with any partner
• Genome-wide direct target identification by CUT&RUN or equivalent in primary granulocyte progenitors not performed
• Mechanism by which R219H reduces repressor binding structurally undefined